Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Bitcoin ETF (BITU) vs Boston Scientific Corporation (BSX) Price & Performance

ProShares Ultra Bitcoin ETFTrade
Boston Scientific CorporationTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Bitcoin ETF vs Boston Scientific Corporation — how do they compare? ProShares Ultra Bitcoin ETF trades at $9.26, while Boston Scientific Corporation trades at $51.15 (market cap $71.46B). The key difference: Boston Scientific Corporation is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.

BITUBSX
Sector
Leveraged / InverseHealth
52-Week High
$64.41$108.14
52-Week Low
$8.12$42.63
Market Cap
$71.46B
Enterprise Value
$83.55B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Bitcoin ETF

BITU trades at $9.64, up 1.69% with neutral technical signals. The stock shows mixed momentum with bullish moving averages but neutral oscillators. Recent dividend payments of $0.01-$0.02 provide shareholder returns, though key financial ratios remain undisclosed in current filings.

The outlook remains cautious with technical indicators showing limited directional bias. Investment opportunity exists through dividend yield, but risks include volatility and lack of clear fundamental data. Analyst sentiment appears neutral with equal buy/sell recommendations.

Boston Scientific Corporation

Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.

BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Ultra Bitcoin ETF

BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.

Read more on BITU

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX